Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLU-808 in Ragweed-Induced Allergic Rhinoconjunctivitis
NCT06922448Phase 2Completed
- Sponsor
- Blueprint Medicines
- Start
- Apr 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BLU-808 in allergic rhinoconjunctivitis (ARC), sponsored by Blueprint Medicines. Started Apr 2025; status: completed.
02
Drugs
BLU-808
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT06922448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922448.